Abstract: The invention relates to methods for activating, inducing or promoting innate immune memory in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof. The invention further relates to methods of improving antimicrobial treatment in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof and to a use of CATH2 or a derivative thereof as an adjuvant for a pathogen-specific vaccine.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The invention relates to the field of antibiotics, more specifically to peptide antibiotics, such as antimicrobial peptides and their use in the treatment of diseases associated with microbial infections. In particular, the invention provides a peptide with antimicrobial activity comprising an amino acid sequence RRWVQRWIRRWR (SEQ ID NO: 24) or an analogue thereof.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The invention relates to the field of antibiotics, more specifically to peptide antibiotics, such as antimicrobial peptides and their use in the treatment of diseases associated with microbial infections. In particular, the invention provides a peptide with antimicrobial activity comprising an amino acid sequence RRWVQRWIRRWR (SEQ ID NO: 24) or an analogue thereof.

Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retro-inverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Abstract: The present invention relates to a novel polypeptide having specific modifications compared to the natural polypeptide. The said novel polypeptide has improved binding characteristics. The present invention also relates to a method of obtaining the said novel polypeptide and to the use of the said novel polypeptides for the treatment of respiratory disorders.